Huang et al.125 found that treating drug-resistant NPC cells with sunitinib could promote the expression of nature killer group 2 member D ligands (NKG2DLs) on the cell membrane by activating the NF-κB signal pathway, thereby enhancing NK cell-mediated cytotoxicity. This evidence concerns the gene NFKB1 and nasopharyngeal carcinoma.